SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (189)5/13/1999 11:30:00 AM
From: scaram(o)uche  Read Replies (2) | Respond to of 555
 
Back when MLNM was kicking around at 17 or so, Michael King of RS told me that he thought it was a $36 stock. That was at a time when the company was underappreciated and good research was selling for a dime on the buck. He has more good calls than bad, IMO.



To: LLCF who wrote (189)5/13/1999 11:49:00 AM
From: Biomaven  Read Replies (1) | Respond to of 555
 
Here's a possibility for an options play: IGEN.

Listening to their CC (available on Vcall) and reading (listening?) between the lines, it sounded to me like a settlement with Roche is a distinct possibility. If so, there's a fair chance of a big pop. So a distant, out-of-the-money call might a good play here. I think the company has a lot going for it, with the Roche dispute as its major problem.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News